Press Releases

Mithra Issues a Put Option Notice Under Capital Agreement with LDA Capital
20 December 2021
EN FR

Mayne Pharma and Mithra Announce TGA Approval of Nextstellis® Oral Contraceptive
29 November 2021
EN FR

Mithra holds today its Investor Day at Mithra CDMO
29 November 2021
EN FR

Information on the Total Number of Voting Rights Following the Completion of the LDA Capital Increase
10 November 2021
EN FR

Mithra organizes its Investor Day on November 29, 2021
10 November 2021
EN FR

Mithra Announces Estelle® Launch in Belgium
21 October 2021
EN FR

The Board of Directors confirms Leon Van Rompay as Mithra’s CEO
15 October 2021
EN FR

Mithra Provides FDA Update on Myring®
6 October 2021
EN FR

Mithra Announces the Appointment of its Representative to Mayne Pharma’s Board of Directors
4 October 2021
EN FR

Interim Financial Report as at 30 June 2021
24 September 2021
EN FR

Mithra Announces Topline Results for COVID-19 Phase II Study
24 September 2021
EN FR

Mithra Announces 2021 Half Year Results
24 September 2021
EN FR

Mithra Announces an Update on PeriNesta®
21 September 2021
EN FR

Donesta® Phase III: Recruitment Completion of American Study and Additional Recruitment in the European Study
21 September 2021
EN FR

Mithra to Host Webcast for Half Year Financial Results on 24 September 2021
17 September 2021
EN FR

Mithra Announces Estelle® Approval in Russia
16 September 2021
EN FR

Mithra and Searchlight Pharma Announce Availability of Nextstellis® in Pharmacies Across Canada
15 September 2021
EN FR

Mithra extends the pricing period for the put option announced on July 2, 2021 under the agreement with LDA Capital
13 August 2021
EN FR

ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments
15 July 2021
EN FR

Mithra Issues a Put Option Notice Under Capital Agreement with LDA Capital
2 July 2021
EN FR

Mithra successfully renegotiates the earnouts relating to its Complex Therapeutics and acquires full licensing and distribution rights for Zoreline®
24 June 2021
EN FR

Estelle® Oral Contraceptive Now Available In The United States
21 June 2021
EN FR

Mithra Completes Recruitment of Covid-19 Phase II Study
17 June 2021
EN FR

Nextstellis® Receives FDA Marketing Exclusivity and Phase III Data Published
27 May 2021
EN FR

Mithra Announces European Approval of Estelle®
20 May 2021
EN FR

Mithra’s General Meeting of Shareholders Approves the Renewal of its Board of Directors
20 May 2021
EN FR

Information on the Total Number of Voting Rights (Denominator)
6 May 2021
EN FR

Mithra takes note of François Fornieri’s indictment
28 April 2021
EN FR

Mithra Releases 2020 Annual Report and Invitation to its Securities holders’ Meeting
20 April 2021
EN FR

Publication of a Transparency Notification Received from Alychlo NV
16 April 2021
EN FR

Mayne Pharma and Mithra Announce FDA Approval of New Oral Contraceptive Estelle®
15 April 2021
EN FR

Richter and Mithra Receive Positive CHMP Opinion for Estelle®
26 March 2021
EN FR

Mithra Reports Full Year 2020 Financial Results
9 March 2021
EN FR

Mithra and Searchlight Pharma Announce Estelle® Approval in Canada
8 March 2021
EN FR

Mithra to Host Webcast for 2020 Financial Results on 9 March 2021
4 March 2021
EN FR

Mithra and Farmitalia Announce Commercial Launch of Myring™ in Italy, the Fourth Largest Market in the World
2 March 2021
EN FR

Estelle® Study Results Published in Leading Peer-Reviewed Medical Journal
9 February 2021
EN FR

The Board of Directors appoints Leon Van Rompay as CEO ad interim
4 February 2021
EN FR

Nomination of Christophe Maréchal as interim CEO
21 January 2021
EN FR

Mithra Announces 2021 Financial Calendar
12 January 2021
EN FR